Zomarist vildagliptin/metformin regulatory update

Germany's Federal Joint Committee (G-BA) said in a final benefit assessment that Zomarist vildagliptin/metformin from Novartis to treat Type II diabetes has "no additional benefit." The assessment is in line with a July preliminary assessment from Germany's Institute for Quality and Efficiency in Healthcare (IQWiG) (see BioCentury, July 15).

Zomarist and 4 other dipeptidyl peptidase-4 (DPP-4) inhibitors are the first group of drugs being assessed under drug pricing law AMNOG that were launched in Germany before the law came into effect in January 2011. Zomarist is a single-tablet combination of Novartis' Type II diabetes drug Galvus vildagliptin, a DPP-4 inhibitor, and metformin. ...